EssilorLuxottica Shares Fall 1.52% at the Close of December 16
EssilorLuxottica shares ended the session on Tuesday, December 16, with a decline of 1.52%, closing at 278.20 euros. This drop extends a corrective movement that has been ongoing for several days, characterized by contained volatility and moderate trading volumes. The stock is now trading below its short and medium-term moving averages, while technical indicators confirm a weakening of bullish momentum.
Daily Trading Details
At the close of December 16, EssilorLuxottica's stock price stood at 278.20 euros, down 1.52% from the previous day's close of 282.50 euros. The share of capital traded remains low at 0.16%, indicating moderate activity in the absence of major catalysts. This new day of decline is part of a marked negative weekly dynamic, with a correction of 8.25% over seven days. The stock is now significantly below its 50-day moving average of 303.58 euros, indicating a short-term technical weakening. However, over longer horizons, performance remains positive with a gain of 4.39% over three months and 20.33% over a year. The stock also remains well above its 200-day moving average of 267.30 euros, maintaining a constructive underlying trend despite the ongoing correction. The support threshold identified at 282.10 euros has been breached, paving the way for a potential test of lower levels.
Technical Analysis Insights
Technical analysis reveals a marked weakening of bullish momentum. The RSI is at 19, a historically low level that signals a pronounced oversold situation and suggests a possible short-term technical rebound. The negative MACD histogram at minus 2.57 points confirms the loss of bullish momentum that has been building over several sessions, with the MACD line at minus 7.85 against a signal line at minus 5.28. The Bollinger Bands frame the stock between 280.53 euros for the lower bound and 323.17 euros for the upper, with the current price dangerously approaching the floor of this channel. The one-month volatility stands at 6.89, a moderate level that reflects an orderly correction without panic movements. The negative CMF at minus 0.35 reveals persistent selling pressure on volumes, while the Scholes signal paradoxically indicates a buying opportunity at these depressed levels.
Recent Strategic Developments
The recent context of the file has been marked by several strategic events. On December 12, the group announced the acquisition of Signifeye, a Belgian ophthalmology platform with 15 clinics in Flanders, as part of its European med-tech expansion. This transaction came days after formalizing a collaboration with the Chips-IT foundation for the development of chips dedicated to connected glasses. On the analyst front, recommendations remain predominantly positive. BNP Paribas Exane raised its price target from 320 to 365 euros on December 10 with an outperformance recommendation, while Goldman Sachs raised its target from 315 to 350 euros on December 5, maintaining its buy recommendation. Morgan Stanley and UBS also display targets ranging between 355 and 365 euros. These forecasts are based on the continued deployment of Ray-Ban Meta connected glasses and the synergies from recent acquisitions in the med-tech sector. The current correction seems more related to profit-taking after the strong year's performance than to a fundamental reassessment of the file.
